Live Breaking News & Updates on Momna ali

Proposed Golimumab Biosimilar AVT05 Meets Primary Endpoints in Moderate to Severe RA

At the end of the trial, the study met its primary outcome, indicating therapeutic equivalence between the biosimilar (AVT05) and reference golimumab.

Robert-wessman , Momna-ali , Cameroni-alvotech , Rheumatology-informatics-system , Clinical-disease-activity-index , Disease-activity , Rheumatoid-arthritis , Globenewswire-news ,

Alvotech's AVT05 emerges as leading contender in rheumatoid arthritis market

The patent for Janssen’s second-generation, tumour necrosis factor-alpha (TNF)-a inhibitor Simponi (golimumab), is scheduled to expire in 2024 and in 2025 in the US and EU, respectively.

Japan , Australia , Advanz-pharma , Momna-ali , Rheumatoid-arthritis , Global-drug-forecast , Market-analysis , Bio-developments , Arkets-amp-regulations , Merging-markets , Heumatoid-arthritis